Home › FDA Grants QIDP And Fast Track Designation To CD101 Topical, Cidara Therapeutics' Novel Antifungal Product Candidate
 

Keywords :   


FDA Grants QIDP And Fast Track Designation To CD101 Topical, Cidara Therapeutics' Novel Antifungal Product Candidate

2016-06-01 05:41:19| drugdiscoveryonline Home Page

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, recently announced that the U.S. Food and Drug Administration (FDA) has designated the company’s novel antifungal product candidate, CD101 topical, as a Qualified Infectious Disease Product (QIDP), with Fast Track status for its development program

Tags: product fast track candidate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05Aptoide sells stake in Faurecia Aptoide Automotive
13.05AppleTV+ fastest growing major SVOD service in Q1'24
13.05SafeShark finds connected devices not compliant with UK security law
13.05Zattoo deploys Bitmovin Player
13.05Altice USA residential video RGUs down 77,700 in 1Q 2024
13.05Fubo unveils new CTV ad offerings at 2024 IAB NewFronts
13.05Liberty Global releases Q1 2024 results
13.05Young face paying mortgage into retirement years
More »